Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Avotermin · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Avotermin | DRUG | - |
Inclusion Criteria: * Male and female patients between 18 and 85 years of age. * Patients undergoing surgical removal of bilateral varicose veins by ligation and stripping, which will result in clinically similar (i.e. size and location) wounds at the groin and knee. * Patients who have provided wr...
Avotermin is an investigational small molecule being studied for use in varicose veins, specifically to treat scars following varicose vein removal. It is in Phase 2 clinical development and is not yet approved by regulatory authorities.
The molecular target of Avotermin has not been disclosed in available information. It is described as a small molecule, but its specific mechanism of action is not publicly detailed.
Avotermin is being developed by Icon Plc, a company listed on the stock exchange under the ticker ICLR. The company is conducting clinical trials to evaluate the drug's safety and efficacy.
Avotermin is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved for commercial use and is still undergoing clinical trials to assess its effects.
Avotermin has one completed Phase 2 trial, NCT00430326, titled 'Juvista (Avotermin) in Scars Following Varicose Vein Removal.' This trial enrolled 156 participants and was conducted in Belgium, Latvia, Lithuania, and the United Kingdom.
Yes, Avotermin is also known as Juvista. The clinical trial NCT00430326 refers to the drug as Juvista (Avotermin), indicating that these names are used interchangeably for the same investigational product.